30 closest matches · ranked by relevance
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Adrenocortical Carcinoma
Primary: Assessment of Clinical Benefit Due to Treatment With Sunitinib — 5 Participants
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Recurrent Adrenocortical Carcinoma · Stage III Adrenocortical Carcinoma · Stage IV Adrenocortical Carcinoma
Primary: The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response…
Metastatic Adenoid Cystic Carcinoma · Progressive Disease · Recurrent Adenoid Cystic Carcinoma
Primary: Assess the Objective Response Rate (ORR) to Axitinib and Avelumab Combination According to RECIST 1.1 Criteria. — 18 percentage of participants
Carcinoma, Adrenal Cortical
Primary: Overall Survival — 108; 124 participants
Adenoid Cystic Carcinoma
Primary: Number of Participants Alive With and Without Disease Progression — 4; 6; 28 Participants
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Renal Cell Carcinoma
Primary: Follow-up Duration — 1.07 years
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Objective Response According to RECIST 1.1 Criteria — 2; 27; 1 Participants
Adenoid Cystic Carcinoma
Primary: Overall Response Rate — 0; 3; 25; 4 Participants
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
Adenoid Cystic Carcinoma
Primary: Determine the Objective Tumor Response Rate Following Treatment With TKI258 — 2; 22; 10 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate — .083 proportion of participants
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
Metastatic Renal Cell Carcinoma · Renal Cell Carcinoma With Sarcomatoid Features
Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Adenoid Cystic Carcinoma
Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival With Sunitinib as First Line of Therapy — 18.4 months
Breast Cancer
Primary: Disease-free Survival — 57; 69 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
Recurrent Non-small Cell Lung Cancer
Primary: Objective Response Rate — 0; 0 percentage of responding patients
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Malignant Ovarian Epithelial Tumor · Ovarian Granulosa Cell Tumor · Ovarian Gynandroblastoma
Primary: Tumor Response — 16.7 percentage of patients
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants